Form 4: CARGO Therapeutics Director David Lubner Granted 25,000 Stock Options

CARGO Therapeutics, Inc. Director David Charles Lubner was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.

Summary

• David Charles Lubner, a Director of CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options on June 18, 2025.
• The stock options have an exercise price of $4.35 per share.
• The options are set to vest 100% on the earlier of the one-year anniversary of June 18, 2025, or the next Annual Meeting following June 18, 2025, contingent upon Mr. Lubner's continued service to the Issuer.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Lubner beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning management interests with shareholder value. This is generally viewed as a neutral to slightly positive event as it incentivizes long-term performance.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value of CARGO Therapeutics, Inc.
• This is a standard practice in corporate compensation, indicating ongoing commitment and incentivization for key personnel.

Future Outlook

The document indicates a future vesting event for the granted stock options, occurring on the earlier of June 18, 2026, or the next Annual Meeting following June 18, 2025, subject to continued service.

Industry Context

The granting of stock options to directors is a common and widely accepted practice across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term value creation is paramount. This type of compensation is designed to align the interests of directors with those of shareholders by providing an incentive tied to the company's stock performance.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and director compensation packages across publicly traded companies, including those in the biotechnology sector like CARGO Therapeutics, Inc.
• This practice is consistent with compensation strategies employed by comparable companies to incentivize long-term commitment and performance, such as those seen at other emerging biotech firms where equity participation is a key retention and motivation tool.

Corporate Governance

Related Party Transactions

• Grant of 25,000 stock options to David Charles Lubner, a Director of CARGO Therapeutics, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation. However, potential future exercise of these options could lead to minor dilution of existing shares.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Vesting of the 25,000 stock options on the earlier of June 18, 2026, or the next Annual Meeting following June 18, 2025, subject to continued service.
• Potential exercise of the vested options by David Lubner before the expiration date of June 17, 2035.

Key Dates

Recommendation

Keywords

CARGO Therapeutics, CRGX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, David Lubner, Equity Compensation